Sometimes science is not as convenient as we would like it to be. We want answers, we want clarity, we want direction–especially when it comes to the treatment of patients with cancer.
So when I read two articles and an editorial released Wednesday in the New England Journal of Medicine, I was struck as to how studies seeking to answer similar questions could come to different conclusions. And, as I struggled to explain the research findings to reporters prior to their release to the general public, I found myself searching for words that would adequately explain the message of the research. Quite frankly, determining that message proved to be difficult. [more]
The studies were done by well-recognized and accomplished researchers, one group from Germany and one from a group based in the United States. The goals of the studies were to demonstrate whether or not the addition of Avastin® (bevacizumab) to chemotherapy treatment given before a woman with breast cancer had surgery improved the rate of complete response of the cancer at the time of surgery (meaning that when the surgeon did the surgery and the pathologist reviewed the specimens there was no evidence of cancer in the … Continue reading →